Pfizer Buys Biotech Company Seagen for More Than 43 Billion Dollars

The American pharmaceutical company Pfizer, known for its corona vaccine, is taking over the American biotechnology company Seagen for 43 billion dollars.

Business newspaper The Wall Street Journal previously reported that the two parties were in talks about a possible takeover.

With the acquisition, Pfizer is expanding its cancer treatments, with which the pharmaceutical company is trying to absorb the expected drop in sales of its corona vaccine. Pfizer announced that sales are expected to fall by a third this year.

This is mainly because there is less demand for the corona vaccine, which Pfizer developed with the German BioNTech.

Pfizer is paying $229 per share in cash for Seagen. That’s about a third more than the drugmaker’s closing price of $172.61 on Friday. Pfizer expects to fund the transaction with the issuance of $31 billion in new, long-term bond issues and a combination of short-term financing and cash.

The Seagen acquisition will contribute more than $10 billion to Pfizer’s revenue by 2030.

Leave a Reply

Next Post

Regional Banks Plummet on Reluctant Wall Street

Mon Mar 13 , 2023
The smaller regional banks in the United States fell hard on the stock exchanges in New York on Monday. The unrest surrounding the collapsed Silicon Valley Bank (SVB) held stock market trading in its grip. The American authorities have intervened, guaranteeing that all SVB customers will receive their credits back. […]
Regional Banks Plummet on Reluctant Wall Street

You May Like

Quick Links